Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Retained Earnings (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Retained Earnings for 16 consecutive years, with -$515.9 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 4.54% to -$515.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$515.9 million through Dec 2025, down 4.54% year-over-year, with the annual reading at -$515.9 million for FY2025, 4.54% down from the prior year.
  • Retained Earnings for Q4 2025 was -$515.9 million at Plus Therapeutics, down from -$510.2 million in the prior quarter.
  • The five-year high for Retained Earnings was -$436.2 million in Q1 2021, with the low at -$515.9 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$476.5 million, with a median of -$476.7 million recorded in 2023.
  • The sharpest move saw Retained Earnings fell 2.32% in 2021, then dropped 5.61% in 2025.
  • Over 5 years, Retained Earnings stood at -$442.8 million in 2021, then decreased by 5.51% to -$467.2 million in 2022, then dropped by 2.85% to -$480.5 million in 2023, then dropped by 2.7% to -$493.5 million in 2024, then decreased by 4.54% to -$515.9 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$515.9 million, -$510.2 million, and -$505.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.